How to Get Addyi in Alaska: Telehealth, Prescriptions, and Pharmacies

What Is Addyi and Why Does It Require a REMS Program?

Flibanserin (brand name Addyi) is the first FDA-approved pharmacologic treatment for generalized acquired hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. The FDA granted approval on August 18, 2015, following three key trials. Because of a clinically meaningful risk of severe hypotension and syncope when combined with alcohol or CYP3A4 inhibitors, the FDA mandated a Risk Evaluation and Mitigation Strategy (REMS) program at the time of approval [1].

Under the REMS, every prescriber must complete a short online certification module, and every dispensing pharmacy must be enrolled before filling a prescription [2]. Patients sign a patient-provider agreement form acknowledging the alcohol restriction. The REMS does not restrict which clinical specialty can prescribe, meaning gynecologists, primary care physicians, psychiatrists, nurse practitioners, and physician assistants are all eligible once certified.

The three key trials that supported the FDA filing included BEGONIA (published in the Journal of Sexual Medicine, 2014), which randomized 1,378 premenopausal women to flibanserin 100 mg nightly vs. placebo over 24 weeks [3]. Satisfying sexual events increased by 2.5 per month in the flibanserin arm versus 1.5 per month in placebo (P<0.001), and the Female Sexual Distress Scale-Revised score improved by 21.9 points vs. 14.8 points [3]. The most common adverse effects were dizziness (11.4%), somnolence (11.2%), nausea (10.4%), and fatigue (9.2%) [3].

Alaska-Specific Prescribing Rules

Alaska permits telehealth prescribing of controlled and non-controlled medications after a synchronous audio-visual encounter, consistent with Alaska Statute 08.64.364 governing telemedicine [4]. Flibanserin is not a controlled substance (DEA Schedule), so the prescribing threshold is lower than for medications such as buprenorphine or testosterone. A prescriber licensed in Alaska, or licensed in another state with a valid interstate telehealth agreement, may issue a flibanserin prescription electronically after confirming HSDD diagnosis criteria are met.

The Alaska State Medical Board does not require an in-person physical examination before a telehealth prescription for non-controlled drugs, provided the prescriber documents a thorough clinical history, reviews relevant medications for CYP3A4 interactions, and obtains a signed REMS patient-provider agreement [4]. Nurse practitioners in Alaska practice under full practice authority without mandatory physician oversight, meaning a certified NP can independently prescribe Addyi after REMS enrollment [5].

For rural and remote patients across the Alaskan interior or the Aleutian Islands, asynchronous store-and-forward telehealth is accepted by some platforms for initial intake questionnaires, but the FDA REMS program requires a prescriber to personally review and sign off on each new patient's agreement form. That final step typically requires a brief live video call [2].

Step-by-Step: Getting an Addyi Prescription in Alaska

Step 1. Find a REMS-certified prescriber. The Addyi REMS website (addyi.com/rems) maintains a directory of enrolled prescribers. As of 2025, several telehealth platforms serving all 50 states hold REMS enrollment and accept Alaska patients. A standard new-patient intake form collects menstrual and sexual history, current medications, and alcohol use patterns.

Step 2. Complete the synchronous video visit. The prescriber screens for contraindications: hepatic impairment (flibanserin is extensively metabolized by CYP3A4 and CYP2C19, and the FDA label states it is contraindicated in patients with any degree of hepatic impairment) [1], use of moderate or strong CYP3A4 inhibitors (fluconazole, clarithromycin, hormonal contraceptives at certain doses), and daily alcohol consumption that cannot be restricted [1].

Step 3. Sign the patient-provider agreement. This is a one-page REMS form that confirms you understand the 2-hour alcohol restriction around each dose and the risk of syncope [2]. Most telehealth platforms offer e-signature.

Step 4. Pharmacy selection. The prescriber transmits the prescription electronically to an Addyi REMS-certified pharmacy. Options for Alaska residents include national mail-order pharmacies certified under the REMS, 503A compounding pharmacies licensed in Alaska, and any retail pharmacy in Anchorage, Fairbanks, or Juneau that has completed REMS enrollment [6].

Step 5. Delivery. USPS Priority Mail and FedEx both deliver to Alaska addresses, including PO Boxes, within 3 to 7 business days from the lower-48 states. For communities on the road system, overnight shipping is available.

Lab Tests Required Before Starting Addyi

Liver function tests are the primary baseline labs recommended before initiating flibanserin. The FDA label explicitly contraindicates flibanserin in patients with hepatic impairment due to an approximate 4.5-fold increase in flibanserin exposure in patients with mild hepatic impairment and an approximately 11-fold increase in patients with moderate impairment [1]. A serum ALT, AST, and total bilirubin drawn within 90 days of initiation is considered adequate by most REMS-certified prescribers.

A complete medication reconciliation is equally important. The FDA label lists the following as contraindicated combinations: moderate or strong CYP3A4 inhibitors (including, but not limited to, ketoconazole, itraconazole, clarithromycin, nefazodone, ritonavir, and several other HIV protease inhibitors) and moderate or strong CYP2C19 inhibitors (fluconazole, for example) [1]. Hormonal contraceptives containing ethinyl estradiol may weakly inhibit CYP3A4, and the label notes the interaction should be discussed but does not constitute a contraindication [1].

A thyroid panel (TSH) and prolactin level are not mandated by the REMS but are clinically reasonable to obtain, because hypothyroidism and hyperprolactinemia are reversible organic causes of low sexual desire that should be excluded before attributing HSDD to a primary psychological or neurochemical etiology [7]. The Endocrine Society's 2019 guideline on female sexual dysfunction states that "organic causes of decreased libido should be evaluated and treated before initiating pharmacologic therapy" [7].

A testosterone level (free and total) drawn in the morning is also advisable to rule out androgen deficiency, which the Endocrine Society notes as a potentially contributing factor in premenopausal women with HSDD, though testosterone therapy is not currently FDA-approved for HSDD [7].

Insurance Coverage and Prior Authorization in Alaska

Alaska Medicaid does not cover flibanserin as of the 2025 formulary cycle. Commercial insurance coverage varies widely. Approximately 30 to 40 percent of commercial plans nationally include Addyi on formulary, typically at Tier 3 or Tier 4 [8]. Prior authorization (PA) is required by most payers that do cover it.

A standard PA submission for flibanserin in Alaska typically requires:

1. A confirmed diagnosis of generalized acquired HSDD (ICD-10 code F52.0 for hypoactive sexual desire dysfunction).
2. Documentation that HSDD has persisted for at least 6 months and causes personal distress (Female Sexual Distress Scale-Revised score >11 is the validated threshold used in the BEGONIA trial) [3].
3. Confirmation that reversible organic causes (hypothyroidism, hyperprolactinemia, relationship distress as the primary driver, medication side effects) have been evaluated [7].
4. A completed REMS patient-provider agreement on file.
5. In some cases, documentation of failure or contraindication to non-pharmacologic treatment (sex therapy, mindfulness-based cognitive behavioral therapy).

The Sprout Pharmaceuticals patient assistance program (PAP) offers free or reduced-cost Addyi for patients with household incomes at or below 400 percent of the federal poverty level who lack insurance coverage. Alaska residents qualify for this program [8]. The manufacturer's copay card reduces out-of-pocket costs to as low as $99 per month for commercially insured patients.

Telehealth Platforms That Serve Alaska for Addyi Prescriptions

Alaska presents geographic access challenges that make telehealth particularly important for HSDD treatment. Several national telehealth platforms have REMS enrollment and accept Alaska addresses for both prescribing and pharmacy fulfillment. When evaluating a platform, confirm three things: REMS enrollment status, ability to e-prescribe to a certified pharmacy shipping to Alaska, and whether the provider holds an Alaska medical license or practices under an interstate compact agreement.

As of early 2025, the Interstate Medical Licensure Compact (IMLC) includes Alaska as a member state, which allows physicians licensed in other IMLC states to treat Alaska patients without a separate Alaska license under specific compact provisions [9]. Nurse practitioners may use the Nurse Licensure Compact (NLC), which Alaska joined in 2016, allowing NPs licensed in compact states to see Alaska patients [5].

A practical screening framework for Alaska telehealth patients requesting flibanserin:

| Step | Clinician action | Typical time | |------|-----------------|--------------| | Intake | Sexual history, FSDS-R score, medication review | 10 to 15 min | | Labs | Order ALT/AST/bilirubin (can use local draw lab in Alaska) | 1 to 3 days | | Video visit | Review labs, sign REMS form, transmit Rx | 15 to 20 min | | Pharmacy | REMS-certified pharmacy ships to Alaska address | 3 to 7 days | | Follow-up | 4-week check-in to assess response and side effects | 10 min |

The FDA label recommends discontinuing flibanserin if no improvement is seen after 8 weeks at the 100 mg nightly dose, as the drug is available only in a single dose strength and no titration is possible [1].

503A Compounding and Flibanserin in Alaska

A 503A pharmacy is a state-licensed compounding pharmacy operating under section 503A of the Federal Food, Drug, and Cosmetic Act [6]. These pharmacies compound medications for individual patients based on a valid prescription. Alaska has active 503A-licensed compounding pharmacies in Anchorage and several other population centers, and out-of-state 503A pharmacies licensed by their home state board may ship to Alaska patients under certain conditions [6].

Compounded flibanserin is not FDA-approved and does not carry the same regulatory assurances as the brand-name product. The FDA has not placed flibanserin on the 503A Bulks List or the 503B Outsourcing Facility drug list, which means a 503A pharmacy compounding flibanserin must meet the standard requirement that the compounded preparation is not essentially a copy of a commercially available drug [6]. Given that Addyi 100 mg tablets are commercially available, most 503A pharmacies do not routinely compound flibanserin unless a specific patient need (such as an excipient allergy or swallowing difficulty) justifies the deviation from commercial product.

Patients should confirm with any compounding pharmacy that the compounded preparation will still require a REMS-compliant prescribing process, because the REMS obligation flows from the drug substance and the prescriber's certification, not exclusively from the brand-name product [2].

Transferring an Existing Addyi Prescription to Alaska

A patient who relocates to Alaska with an active flibanserin prescription from another state can transfer the prescription to an Addyi REMS-certified pharmacy in Alaska or to a mail-order REMS pharmacy already serving their new address. Because flibanserin is not a Schedule II through V controlled substance, there is no federal restriction on interstate prescription transfers for this medication [10].

The transfer process requires the new dispensing pharmacy to verify that both the dispensing pharmacy and the original prescriber hold current REMS enrollment. If the original prescriber is not licensed in Alaska and the patient no longer has an established relationship with an Alaska provider, the patient will need a new evaluation with an Alaska-licensed or compact-eligible prescriber to continue the prescription [4]. This new evaluation can be conducted via synchronous telehealth, so it does not require travel to a clinic.

Efficacy Data: What Patients in Alaska Should Expect

The three key trials submitted to the FDA used a 24-week treatment period and measured two co-primary endpoints: the number of satisfying sexual events (SSEs) per month as recorded in an e-diary, and the Female Sexual Distress Scale-Revised (FSDS-R) total score [3]. Across all three trials, flibanserin produced a statistically significant improvement in SSEs and FSDS-R compared to placebo, though the absolute magnitude was modest.

In BEGONIA (N=1,378), the mean increase from baseline in SSEs was approximately 1.0 events per month more than placebo [3]. The FDA reviewers noted that this magnitude, while statistically significant at P<0.001, represents a clinically modest effect, and the prescriber-patient discussion should address realistic expectations [1]. Approximately 60 percent of patients in the key trials reported at least some subjective improvement in desire [3].

The 2015 FDA advisory committee voted 18 to 6 in favor of approval, with the condition that the REMS program be implemented to manage the hypotension-alcohol interaction risk [1]. An independent analysis of the three trials published in JAMA Internal Medicine (Jaspers et al., 2016) found that for every 10 women treated with flibanserin, one additional woman experienced a satisfying sexual event per month compared to placebo [11]. This number-needed-to-treat framing is worth sharing with patients during the informed consent discussion.

What Happens If Addyi Is Not the Right Fit

If a patient does not respond after 8 weeks of 100 mg flibanserin nightly, or if side effects (most commonly somnolence and dizziness) are intolerable, the prescriber has several options. Bremelanotide (Vyleesi), a melanocortin receptor agonist approved by the FDA in June 2019 for acquired generalized HSDD in premenopausal women, is a subcutaneous injection taken as needed (not daily) and does not carry the alcohol interaction restriction that flibanserin carries [12]. It represents a distinct mechanism and may suit patients who prefer on-demand dosing.

Off-label options discussed in the Endocrine Society guidelines include low-dose testosterone (compounded, since no FDA-approved testosterone formulation exists for women in the United States) and bupropion, both of which carry their own evidence bases and risk profiles [7]. A telehealth provider in Alaska can discuss all of these options during the same visit, and the Alaska telehealth rules permit prescribing bupropion and compounded testosterone after appropriate evaluation [4].